Novastra
Novastra Therapeutics develops therapies using its Next-Generation System-Level Immune Reprogramming (XIRT) platform to address immune-excluded tumors. The OmniAntigen Platform captures tumor signatures and delivers upstream priming to generate a polyclonal T-cell response. This approach engineers immune responses to treat patients refractory to checkpoint inhibitors.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Novastra Therapeutics develops therapies using its Next-Generation System-Level Immune Reprogramming (XIRT) platform to address immune-excluded tumors. The OmniAntigen Platform captures tumor signatures and delivers upstream priming to generate a polyclonal T-cell response. This approach engineers immune responses to treat patients refractory to checkpoint inhibitors.